Mednax Reaches New 52-Week High (MD)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Mednax (NYSE: MD) hit a new 52-week high Thursday as it is currently trading at $86.16, above its previous 52-week high of $85.27 with 68,199 shares traded as of 10:11 a.m. ET. Average volume has been 439,200 shares over the past 30 days.

Mednax has a market cap of $4.24 billion and is part of the health care sector and health services industry. Shares are up 6.6% year to date as of the close of trading on Wednesday.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, maternal-fetal, other pediatric subspecialties, and anesthesia physician services in the United States and Puerto Rico. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Mednax Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Why the Boardroom Doesn't Need Ivy League Degrees

Mednax: Solid Growth at a Good Price

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

How to Invest in Your Favorite MD